Enlivex Therapeutics Ltd.
ENLVHealthcare|Biotechnology|IL
$1.27
+0.00 (+0.00%)
Tangible Book / Share
$2661.47
Graham Number
$18359.01
Cash / Share
$5.34
Clinical Trials (10)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT07580716 Intra-Articular Allocetra in Patients With Primary Knee Osteoarthritis | Primary Knee Osteoarthritis | P2 | Recruiting | 182 | RCT, Double-blind | Allocetra |
| NCT06208241 Use of Allocetra-OTS in End Stage Knee Osteoarthritis - Assessment of Safety | Knee Osteoarthritis | Early P1 | Active | 18 | Open-label | Allocetra-OTS |
| NCT06233474 Study of Intra-articular Allocetra in Knee Osteoarthritis | Osteoarthritis, Knee | P1P2 | Completed | 134 | RCT, Double-blind | Allocetra |
| NCT04922957 A Phase 2b Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study, Evaluating Efficacy and Safety of Allocetra-OTS in Patients With Severe or Critical COVID-19 With Associated Acute Respiratory Distress Syndrome (ARDS) | Covid19 | P2 | Terminated | 12 | RCT, Double-blind | ALLOCETRA-OTS |
| NCT05431907 Phase 1/2 Study Evaluating Safety and Potential Efficacy of Allocetra-OTS Via Pressurized Intra-Peritoneal Aerosol Chemotherapy as Add-on to Standard of Care Chemotherapy for Treatment of Peritoneal Metastasis | Peritoneal Metastases | P1P2 | Terminated | 9 | Open-label | Allocetra-OTS |
| NCT04612413 A Phase 2 Study Evaluating Efficacy, Safety and Tolerability of Different Doses and Regimens of Allocetra-OTS for the Treatment of Organ Failure in Adult Sepsis Patients | Sepsis, Community-acquired Pneumonia | P2 | Completed | 148 | RCT, Double-blind | Allocetra-OTS |
| NCT05581719 A Phase 1/2a Study Evaluating Allocetra-OTS as Monotherapy or in Combination With Anti-PD-1 Therapy for the Treatment of Advanced Solid Tumor Malignancy | Solid Tumor, Peritoneal Metastases | P1P2 | Terminated | 14 | Open-label | Allocetra-OTS, Nivolumab, Tislelizumab |
| NCT03925857 Prevention of Sepsis-related Organ Dysfunction With Allocetra-OTS | Organ Dysfunction Syndrome Sepsis | P1 | Completed | 10 | Open-label | Allocetra-OTS |
| NCT06522035 Evaluation of Allocetra by Intra-articular Injection for the Treatment of Psoriatic Arthritis | Arthritis, Psoriatic | P1 | Terminated | 5 | Open-label | Allocetra |
| NCT04659304 Study Evaluating Safety and Tolerability of Allocetra-OTS in Patients With COVID-19 | Covid19 | P1 | Unknown | 18 | RCT, Open-label | Allocetra-OTS |